Lundbeck: Myriad Deal is a High Risk High Reward Strategy - RedOrbit
Lundbeck: Myriad Deal is a High Risk High Reward Strategy RedOrbit, TX - Lundbeck has acquired the European commercialization rights to Myriad's new Alzheimer's treatment, Flurizan. However, late stage failures are common in the ... |
Original post: Lundbeck: Myriad Deal is a High Risk High Reward Strategy - RedOrbit by ©2008 Google at alzheimers treatment - Google News
Blog tag: Alzheimers treatment
Technorati tag: Alzheimers treatment